Treatment Information

Back

Prostate Cancer treatment details. Biologic therapy.

Warren Grant Magnuson Clinical Center, NIH, Bethesda, MD, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:Bethesda, MD
Treatments:Biologic therapyHospital:Warren Grant Magnuson Clinical Center, NIH
Drugs:Journal:Link
Date:Mar 2005

Description:

Patients: This Phase II study involved 72 men with hormone refractory malignant prostate cancer with bone metastases. The patients were randomly divided into two groups. Group B had 36 patients with a median age of 72.

Treatment: For Group B, the treatment consisted of ketoconazole which is an antifungal medication and alendronate which is in a class of medications used to strengthen bone.

Toxicity: No grade 4-5 toxicities were observed. For Group B, grade 1-3 toxicities included fatigue, hyperglycemia, and increased liver enzymes.

Results: The median overall survival for both groups was 24.7 months. Group A's median survival was 19 months. Group B's median survival was not determined. However, the authors reported no significant difference between the response rates, progression-free survival, and overall survival between Group A and Group B.

Correspondence: William D. Figg, MD



Back